Accolade, Inc. ACCD
Set alert
At close · Apr 8
52-week range unavailable
- YTD
- +105.26%
- 1 year
- -23.61%
- Open
- 7.02
- Prev close
- 7.02
- Mkt cap
- 273.83M
- Vol
- 4.54M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.02
- High
- 7.02
- Forward P/E
- -4.05
- Beta
- 2.02
- Short ratio
- 2.59
- Inst. own
- 83.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 9, 2025
- 50-d avg
- 3.51
- 200-d avg
- 5.37
- 1y target
- 7.17
Key statistics
- Market cap
- 273.83M
- Enterprise value
- 284.73M
- Trailing P/E
- 0.00
- Forward P/E
- -4.05
- PEG ratio
- 0.00
- Price / sales
- 0.62
- Price / book
- 0.65
- EPS (TTM)
- -1.02
- Beta
- 2.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -18.16%
- Revenue (TTM)
- 441.03M
- Revenue growth
- 9.80%
- Free cash flow
- 33.37M
- Total cash
- 234.35M
- Total debt
- 238.81M
- Return on equity
- -18.61%
- Shares outstanding
- 80.54M
- Short % of float
- 4.02%
- 50-day average
- 3.51
- 200-day average
- 5.37
Analyst view
Consensus: buy
- Target (low)
- 5.00
- Target (mean)
- 7.17
- Target (high)
- 9.50
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Jan 9, 2025
Expected Jan 9, 2025. Consensus EPS estimate -0.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 9, 2025 | Nov 1, 2024 | -0.31 | — | — | — |
| Oct 8, 2024 | Aug 1, 2024 | -0.45 | -0.30 | +0.15 | +33.33% |
| Jun 27, 2024 | May 1, 2024 | -0.48 | -0.35 | +0.13 | +27.08% |
| Jun 27, 2024 | May 1, 2024 | -0.48 | — | — | — |
| Apr 25, 2024 | Feb 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Apr 25, 2024 | Feb 1, 2024 | -0.11 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 11, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 9, 2024 | Truist Securities | main | Buy | Buy |
| Oct 9, 2024 | Canaccord Genuity | main | Buy | Buy |
| Oct 9, 2024 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 9, 2024 | Stephens & Co. | main | Overweight | Overweight |
About Accolade, Inc.
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- accolade.com
News
- Del Taco Celebrates Best Fast Food Restaurant Accolade with Free Tacos for a Year Promotion for 7,000 New Mexico Fans
- Vontier Earns Top Accolade at International Sustainability Awards
- Scripps Cancer Center Leader Receives National Accolade
- Defining Wellness Centers Names Bill Morrison Chief Financial Officer
- CoinEx Wins Top Accolade for Cryptocurrency Exchange at International Business Magazine Awards 2025
- TalkingParents Takes Home 11th Accolade For Support Network Initiative
- The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade
- Wellspring Launches Next-Gen Innovation Platform, Accolade Core
- Pernod completes sale of wine portfolio to Accolade Wines owner
- Digital health startup Transcarent takes Accolade private in $621 million deal
Your note
Sign in to keep a note on ACCD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNES STEPHEN H. | Chief Financial Officer | Sale | Dec 16, 2024 | 220,463 |
| BRODSKY JEFFREY S | Director | Conversion of Exercise of derivative security | Dec 1, 2024 | 44,632 |
| CAVANAUGH ROBERT N | President | Sale | Dec 16, 2024 | 213,295 |
| ESKEW RICHARD | General Counsel | Sale | Dec 2, 2024 | 62,507 |
| HILTON MICHAEL W. | Director | Conversion of Exercise of derivative security | Dec 15, 2024 | 345,988 |
| KLEIN PETER S | Director | Conversion of Exercise of derivative security | Aug 5, 2024 | 28,329 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.75% | 6,240,828 | 21.22M | Sep 29, 2024 |
| Ah Capital Management, L.L.C. | 6.70% | 5,398,708 | 18.36M | Sep 29, 2024 |
| ARK Investment Management, LLC | 6.68% | 5,382,533 | 18.30M | Sep 29, 2024 |
| Brown Advisory Inc. | 5.99% | 4,824,662 | 16.40M | Sep 29, 2024 |
| Vanguard Group Inc | 5.16% | 4,157,154 | 14.13M | Sep 29, 2024 |
| Millennium Management Llc | 4.95% | 3,987,883 | 13.56M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 6.49% | 5,223,950 | 17.76M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.75% | 2,213,022 | 7.52M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.28% | 1,837,885 | 6.25M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.41% | 1,139,503 | 3.87M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.94% | 759,285 | 2.58M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.57% | 463,027 | 1.57M | Oct 30, 2024 |